论文部分内容阅读
背景及目的:Denosumab为一种人类单克隆抗体,它是核因子B配体(TANK)的受体激活剂(RANKL),RANKL能够阻断该受体与RANK结合,从而抑制破骨细胞的生长及作用,减少骨的再吸收,增强骨密度。本研究分析了该药物对绝经后妇女骨质疏松症的预防作用。
BACKGROUND & OBJECTIVE: Denosumab is a human monoclonal antibody that acts as a receptor activator of nuclear factor B ligand (RANK). RANKL blocks the binding of this receptor to RANK and thus inhibits osteoclast growth And the role of reducing bone resorption and increase bone mineral density. This study analyzed the prophylactic effect of the drug on osteoporosis in postmenopausal women.